Table 3 Description of patients who achieved pCR
Characteristics | Total | pCR | Non-pCR | p |
|---|---|---|---|---|
Total, n | 80 | 26 | 54 | |
Age, years | 0.08 | |||
Mean | 51.3 | 46 | 53 | |
Range | 26–80 | 32–69 | 26–80 | |
95% CI | 48.6–54 | 36.7–61 | 47–58 | |
Age group | 0.02 | |||
20–39 | 17 (21.3) | 10 (58.8) | 7(41.2) | |
40–59 | 38 (47.5) | 8 (21.1) | 30 (78.1) | |
≥ 60 | 25 (31.2) | 8 (32) | 17 (68) | |
T prior to NAC, n (%) | 0.49 | |||
cT1 | 10 (12.5) | 5 (50) | 5 (50) | |
cT2 | 52 (65) | 17 (32.7) | 35 (61.3) | |
cT3 | 12 (15) | 3 (25) | 9 (75) | |
cT4 | 6 (7.5) | 1 (16.7) | 5 (83.3) | |
N prior to NAC, n (%) | 0.63 | |||
cN0 | 39 (48.8) | 15 (38.5) | 24 (61.5) | |
cN1 | 26 (32.5) | 6 (23.1) | 20 (76.9) | |
cN2 | 6 (7.5) | 2 (33.3) | 4 (66.7) | |
cN3 | 9 (11.2) | 3 (33.3) | 6 (66.7) | |
Primary tumour diameter, mm | 0.54 | |||
Mean | 32.6 | 33.3 | 31.2 | |
Range | 10–70 | 10–70 | 12–55 | |
95% CI | 29.5–35.8 | 29.3–37.8 | 25.9–36.5 | |
NAC regimen, n (%) | 0.09 | |||
Platinum containing | 47 (58.7) | 19 (40.4) | 28 (59.6) | |
Nonplatinum containing | 33 (41.3) | 7 (21.2) | 26 (78.8) | |
Germline BRCA1/2, n (%) | 0.001 | |||
Pathogenic variant | 26 (32.5) | 15 (57.7) | 11 (42.3) | |
BRCA1 c.5117G > A | 6 (7.5) | 5 (83.3) | 1 (16.7) | |
BRCA1 c.5266dupC | 11 (13.8) | 7 (63.6) | 4 (36.4) | |
BRCA1 c.4035delA | 5 (6.2) | 1 (20) | 4 (80) | |
BRCA1 c.4675G > A | 1 (1.25) | 0 (0) | 1 (100) | |
BRCA1 c.843_846del | 1 (1.25) | 1 (100) | 0 (0) | |
BRCA1 c.181 T > G | 1 (1.25) | 1 (100) | 0 (0) | |
BRCA2 c.1813dupA | 1 (1.25) | 0 (0) | 1 (100) | |
Wild type or unknown | 54 (67.5) | 11 (20.4) | 43 (79.6) | |
Ki67, n (%) | 0.007 | |||
Low (< 50%) | 40 (50) | 7 (17.5) | 33 (82.5) | |
High (≥ 50%) | 40 (50) | 19 (47.5) | 21 (52.5) |